ItalyItaly

Toxicity Test to cut Animal Testing

09.04.2004

Milan/Rome - Italian researchers have developed a new cell culture method to test whether chemicals are toxic to humans. They engineered liver cells (hepatocytes) to secrete the human growth hormone (HGH) when exposed to toxic organic or inorganic compounds like Sodium arsenite, Benzopyrene, or Tetra-chloro hydro quinone. Additionally the transgenic hepatocyte cell line has been stably immortalized by insertion of the growth factor receptor gene c-met. As the novel cell lines can survive for longer than cultured primary liver cells, the cell type most commonly used in toxicity testing, adopting this new technique would reduce the number of animals used in such experiments.
To create the bi-transgenic cell line researchers around Marco Tripodi crossed two mice strains they previously created: A strain in which the gene for the human growth hormone (hGh) is constructed behind a heat-shock protein promotor (hsp70). Additionally, a mouse model allowing the reproducible immortalization of untransformed hepatocytes retaining complex liver functions.
To test their system the researchers added toxic arsenic and cadmium compounds to the cells and then looked for human growth hormone in the culture media. They found that even at low doses these compounds caused the cells to secrete the hormone - and were therefore deemed to be toxic. These low concentrations of the chemicals would not have been picked up by current toxicity-testing methods, which brand a chemical as ‚toxic' only if it kills liver cells.
The researchers believe that experiments using the transgenic cell lines will also be more informative than those using cultured liver cancer cell lines, the current alternative to cultured primary cells. Over time, liver cells in culture are known to alter their patterns of gene expression and no longer behave like liver cells in vivo. For example they often lose the ability to produce drug-activating and modifying enzymes. Cultured MMH-GH cell lines do not suffer from this problem, retaining features of liver cells inside the mouse. Moreover, if important changes do occur in these cells, fresh cell lines can be derived from the transgenic animals. The MMH-GH cell lines have a further advantage over current toxicity testing methods, according to the researchers. As they are derived from clonal cell populations assays using these cells should also be easier to standardize than current tests, which use heterogeneous primary cell cultures.

ItalyItaly

07.03.2012

Toscana Biomarkers S.r.l has entered the market for biomarkers with its first diagnostic kit. In late January, the company from Siena signed a licence agreement with DIESSE Ricerche S.r.l, based in Genoa. DIESSE will produce and...

ItalyItaly

07.03.2012

Italian researchers have reprogrammed neonatal cardiomyocytes into iPSCs that can re-differentiate toward CMs more efficiently than either cardiac fibroblast-derived iPS cells or even ES cells. (Cell Death Differ.,...

ItalyItaly

09.01.2012

Rome – A cold virus isolated from chimpanzees might work as an vector for human vaccines. Adenoviruses are principally suitable as vectors for vaccines for their ability to induce strong immune responses. But as most humans have...

ItalyItaly

16.12.2011

Milan/Turku – Italian drug developer Newron SpA has had a roller-coaster ride in the last few months. First Merck Serono decided to drop its stake in the company’s Parkinson’s Disease candidate salfinamide, and returned the...

ItalyItaly

15.12.2011

Genoa/Irvine – Researchers from the universities at Genoa and Irvine (US) have patented a new compound that blocks removal of the endo­cannabinoid painkiller anandamide from the synaptic space by a selective transport system....

ItalyItaly

01.10.2011

Parma/Baranzate – Chiesi Farmaceutici Spa has said it will lengthen its long-term collaboration with NiKem Research, which is focused on developing treatments within the respiratory therapeutic area. The two drug developers have...

ItalyItaly

01.10.2011

Milan/Turku – Biotie Therapies ASA’s announcement that it had signed an agreement to acquire Newron Pharma­ceuticals S.p.A. for €45m is both good and bad news for the Italian biotechnology sector. While Italy is losing one of its...

ItalyItaly

19.08.2011

Como – Shares in Gentium SpA lost about a third of their value on Thursday after The Italian biopharmaceutical company withdrew a marketing application for its drug Defibrotide being used against complications related to stem...

ItalyItaly

01.08.2011

Milan/London – Italy’s MolMed SpA has signed a deal with UK-based pharmaceutical giant GlaxoSmithKline to develop a production process for a gene therapy against the rare ‘bubble boy disease’. Over the next two years, GSK will...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-italy/article/toxicity-test-to-cut-animal-testing.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.55 CHF99.3%
  • ADDEX (CH)4.08 CHF85.5%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-29.1%
  • PROSENSA (NL)9.48 USD-26.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP780.4%
  • PAION (D)2.79 EUR304.3%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.48 USD-68.2%

No liability assumed, Date: 24.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products